More on Charles River Labratories (CRL): Q4 beats both revenue and per share estimates on better...

|About: Charles River Laboratories ... (CRL)|By:, SA News Editor

More on Charles River Labratories (CRL): Q4 beats both revenue and per share estimates on better than expected product demand and the absence of prior-year write-downs. The company also reafirms FY12 guidance.